Hui Yuan - Luye Pharma CoFounder Director
| LYPHF Stock | USD 0.34 0.00 0.00% |
Director
Hui Yuan is CoFounder Director of Luye Pharma Group
| Age | 64 |
| Web | https://www.luye.cn |
Luye Pharma Management Efficiency
Luye Pharma's management efficiency ratios could be used to measure how well Luye Pharma manages its routine affairs as well as how well it operates its assets and liabilities.Similar Executives
| Showing other executives | DIRECTOR Age | ||
| Marcus Wallenberg | AstraZeneca PLC ADR | 63 | |
| Ton Buechner | Novartis AG ADR | 55 | |
| Glenn Tilton | AbbVie Inc | 72 | |
| Karen Walker | Eli Lilly and | 59 | |
| Deborah DiSanzo | AstraZeneca PLC ADR | 59 | |
| Srikant Datar | Novartis AG ADR | 67 | |
| Mike Ciaffi | Scilex Holding | N/A | |
| Nancy Andrews | Novartis AG ADR | 63 | |
| Nazneen Rahman | AstraZeneca PLC ADR | N/A | |
| Jamere Jackson | Eli Lilly and | 52 | |
| Joseph Echevarria | Pfizer Inc | 64 | |
| Shantanu Narayen | Pfizer Inc | 57 | |
| Jackson Tai | Eli Lilly and | 71 | |
| Bridgette Heller | Novartis AG ADR | 59 | |
| Sherilyn McCoy | AstraZeneca PLC ADR | 60 | |
| Mary Beckerle | Johnson Johnson | 66 | |
| Dinesh Paliwal | Bristol Myers Squibb | 63 | |
| Raul Alvarez | Eli Lilly and | 65 | |
| Susan DesmondHellmann | Pfizer Inc | 63 | |
| Paul Rothman | Merck Company | 63 | |
| Karen Vousden | Bristol Myers Squibb | 63 | |
Management Performance
| Return On Equity | -0.0261 | |||
| Return On Asset | 0.0081 |
Luye Pharma Group Leadership Team
Elected by the shareholders, the Luye Pharma's board of directors comprises two types of representatives: Luye Pharma inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Luye. The board's role is to monitor Luye Pharma's management team and ensure that shareholders' interests are well served. Luye Pharma's inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Luye Pharma's outside directors are responsible for providing unbiased perspectives on the board's policies.
| Rong Yang, CoFounder Chairman | ||
| Yuan Liu, Chief Officer | ||
| Yuan Zhu, Ex Director | ||
| Yun Xue, VP Luye | ||
| Li Loh, Assistant Sec | ||
| Dian Liu, Exec CoFounder | ||
| Hui Yuan, CoFounder Director | ||
| ACIS ACS, Company Sec | ||
| Zhi Fan, Chief Ltd | ||
| You Li, Head VP |
Luye Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right pink sheet is not an easy task. Is Luye Pharma a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.0261 | |||
| Return On Asset | 0.0081 | |||
| Profit Margin | (0.04) % | |||
| Operating Margin | 0.06 % | |||
| Current Valuation | 2.08 B | |||
| Shares Outstanding | 3.55 B | |||
| Shares Owned By Insiders | 35.41 % | |||
| Shares Owned By Institutions | 24.08 % | |||
| Price To Book | 2.17 X | |||
| Price To Sales | 0.47 X |
Currently Active Assets on Macroaxis
| BTC | Bitcoin | |
| TRX | TRON | |
| BNB | Binance Coin | |
| ADA | Cardano | |
| XRP | XRP |
Other Information on Investing in Luye Pink Sheet
Luye Pharma financial ratios help investors to determine whether Luye Pink Sheet is cheap or expensive when compared to a particular measure, such as profits or enterprise value. In other words, they help investors to determine the cost of investment in Luye with respect to the benefits of owning Luye Pharma security.